General Cardiology
Science News
Journals
Continuing Education
STRONG HF
Successful Post-Discharge of Heart Failure
Alexandre Mebazaa | University de Paris, Paris, France
- ClinicalTrials ID: NCT03412201
- AHA News Release: Maximizing heart failure meds within 2 weeks reduced risk of hospital readmission, death
TRANSFORM-HF
Comparative Effectiveness of Torsemide versus Furosemide in Heart Failure: Primary Results of the TRANSFORM-HF Trial
Robert J Mentz | Duke University Hospital, Durham, North Carolina
- TRANSFORM-HF trial data summary slide (PPTX)
- ClinicalTrials ID: NCT03296813
- AHA Press Release: TRANSFORM-HF trial found no difference in effectiveness between 2 common loop diuretics
- Short Video: TRANSFORM-HF Results in under 2 minutes
CRISPR ATTR
First-in-Human in vivo CRISPR/Cas9 Editing of the TTR Gene by NTLA-2001 in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Julian D Gillmore | University College of London, London, United Kingdom
- CRISPR-ATTR trial data summary (PPTX)
- AHA Press Release: Novel gene-editing therapy shows promise for patients with transthyretin amyloid cardiomyopathy
- ClinicalTrials ID: NCT04601051
- Original article: NEJM, 2021(link opens in new window)
DCP
Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients With Hypertension
Areef Ishani | Minneapolis VA Health Care System, Minneapolis, Minnesota
- DCP trial data summary slide (PPTX)
- Clinical Trials ID: NCT02185417
- AHA Press Release: No difference in heart outcomes found in use of two diuretics to treat blood pressure
IRONMAN
A Randomized Trial of Intravenous Ferric Derisomaltose in Heart Failure With Reduced Ejection Fraction
Paul R Kalra | Portsmouth Hospital, University NHS Trust, Portsmouth, United Kingdom
- IRONMAN Study Data Slide (PPTX)
- Simultaneously Published in The Lancet (new window)(link opens in new window)
- ClinicalTrials ID: NCT02642562
- AHA Press Release: Intravenous iron improved long-term outcomes for people with heart failure and iron deficiency
PROMINENT
A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of Cardiovascular Disease
Aruna D Pradhan, Brigham and Women's Hospital | Boston, Massachusetts
- PROMINENT Study Data Summary (PPTX)
- PROMINENT: Published in NEJM(link opens in new window)
- Editorial in NEJM
- ClinicalTrials ID: NCT03071692
- AHA Press Release: New medicine reduces triglyceride by 25%, no change in CVD risk in people with Type 2 diabetes
American Heart Association Professional Members
Enjoy instant benefits!
- Free Online Access to AHA Scientific Journals
- Affiliate with our 16 Scientific Councils
- Discounts on Scientific Conference Registration and Online Courses